Taipei-based precision oncology firm Anbogen Therapeutics Inc. drew $12.5 million in a series A funding round to propel two major clinical assets in its cancer pipeline.
Around 75% of breast cancer cases in postmenopausal patients show estrogen receptor (ER) expression. There is a need for new long-acting formulations for selective estrogen receptor degradation inducers (SERDs) because the efficacy of current options, such as the approved SERD fulvestrant, is limited due to poor solubility and stability.
Researchers from The Second Hospital and Yuying Children’s Hospital of Wenzhou Medical University have published results of the preclinical characterization of a novel curcumin analogue, CP-41, being developed as a potential anticancer agent.
Second Affiliated Hospital of Wenzhou Medical University investigators have assessed the functions of FBXO28 on proliferation, migration and invasion in ovarian cancer.
Phyllodes tumors (PTs) are rare, fibroepithelial tumors of the breast that can arise as benign, borderline or malignant. Little is known about the molecular mechanisms behind their occurrence, and it is easy to misdiagnose them as other histologically similar tumors, such as metaplastic breast cancer. It was hypothesized that DNA methylation could be a helper here.
Chengdu Easton Biopharmaceuticals Co. Ltd. has identified cyclin-dependent kinase 7 (CDK7) inhibitors reported to be useful for the treatment of cancer.
Amphiphile (AMP)-modification of peptide antigens and molecular adjuvants has been previously demonstrated to enhance lymphatic delivery and retention, resulting in potent expansion of cognate endogenous T-cell responses.
Radiation therapy resistance (radioresistance) is a key contributor to the failure of rectal cancer treatment, with immunosuppression playing a significant role here.
23andme Holding Co. has received FDA clearance of its IND application for 23ME-01473 (‘1473), a dual mechanism antibody and natural killer (NK) cell activator intended to treat cancer.
Halia Therapeutics Inc. has, its CEO confidently asserts, taken an atypical road to building its infrastructure and financing. The Lehi, Utah-based company just completed a $30 million series C financing to further develop its lead asset, a selective and orally bioavailable first-in-class NLRP3/NEK7 inflammasome inhibitor.
RSS
